


PHARMACEUTICAL 2019



Xenon Pharmaceuticals Inc. Rank 103 of 371





PHARMACEUTICAL 2019



Xenon Pharmaceuticals Inc. Rank 103 of 371

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 261% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Revenues, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is -37%, being 294% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	121,437
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,119
Liabilities, Non-Current	15,014
Other Assets	0
Other Compr. Net Income	0
Other Expenses	7,394
Other Liabilities	0
Other Net Income	4,913
Property and Equipment	991
Research and Development	23,634
Revenues	0
Selling, General and Administrative Expense	8,382

Output Variable	Value in 1000 USD
Assets	122,428
Liabilities	19,133
Expenses	39,410
Stockholders Equity	103,295
Net Income	-34,497
Comprehensive Net Income	-34,497
Economic Capital Ratio	-37%